Agni Bio Selected to Present AGB101 (Vβ17 x DLL3) Poster at AACR Annual Meeting 2026

South San Francisco, CA — March 27, 2026 — Agni Bio, Inc., a biotechnology company developing next-generation immunotherapies, today announced that it has been selected to present a poster highlighting its AGB101 (Vβ17 x DLL3) program at the AACR Annual Meeting 2026 in the Late Breaking Poster Session, taking place April 17–22, 2026 in San Diego and hosted by the American Association for Cancer Research.

The poster will feature preclinical data for AGB101, a first-in-class Vβ17 x DLL3 bispecific antibody designed to selectively redirect a defined subset of cytotoxic memory T cells to tumors. Agni Bio plans to initiate a Phase 1 clinical trial of AGB101 in the second half of 2026.

Key Highlights from the Poster Presentation:

• Novel mechanism of action: AGB101 selectively engages Vβ17 T cell receptor (TCR)–expressing T cells, a memory T cell subset with enhanced cytotoxicity, persistence, and resistance to exhaustion.
• Targeted tumor approach: The molecule targets DLL3, a solid tumor lineage antigen highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors.
• Selective immune activation: Unlike CD3-directed bispecific antibodies which non-selectively redirects the majority of T cells, AGB101 selectively redirects and expands Vβ17 cells to drive DLL3-dependent cytotoxicity.
• Reduced cytokine release profile: Preclinical studies with AGB101 demonstrate lower levels of release of pro-inflammatory cytokines (including TNF-α, IL-4, and IL-1β) while maintaining cytotoxic effector function (Granzyme B), suggesting the potential for an improved safety profile relative to CD3-based approaches.
• Robust anti-tumor activity: AGB101 achieved potent and durable cytotoxicity in vitro and demonstrated complete tumor regressions in multiple DLL3-positive in vivo models.
• Durable and memory-driven responses: Data show selective expansion (up to 10–15-fold) of Vβ17 T cells with a strong CD8+ bias and enhanced anti-tumor activity upon tumor rechallenge.

“AGB101 represents a fundamentally new approach to T cell redirection by selectively harnessing a highly functional subset of memory T cells,” said Matt Lorenzi, PhD, Chief Scientific Officer and Board Member of Agni Bio. “We believe this strategy has the potential to overcome key limitations of first-generation T cell engagers, including toxicity and limited durability, and we are excited to advance this program into the clinic later this year.”

AGB101 is part of Agni Bio’s Vβ17 platform of TCR-directed bispecific antibodies designed to improve the precision and effectiveness of immune engagement in cancer and autoimmune therapies.

About Agni Bio
Agni Bio is a biotechnology company based in South San Francisco, CA, focused on developing innovative therapies to address unmet needs in oncology and autoimmune diseases. The company leverages its proprietary bispecific antibody platforms to advance the next frontier in immune cell redirection therapy.

Contact:
Agni Bio, Inc.
communications@agnibiotx.com